Navigation Links
Frank Phillips, Paul Anderson and Federico Girardi Join SI-BONE's Medical Advisory Board
Date:2/17/2010

innovative, patented, intramedullary implant to treat the SI Joint.   The company is also planning a post-market multicenter study to determine its effect over time on SI Joint pathology and on symptoms associated with SI Joint dysfunction.

The iFuse Implant System is a commercially available device in the US intended for fracture fixation of large bones and large bone fragments of the pelvis for conditions including sacroiliac joint disruptions and degenerative sacroiliitis.  The iFuse procedure uses a minimal incision for delivery and implantation of small, titanium implants.  The implants are coated with a porous plasma spray that acts as an interference surface, designed to help decrease implant motion.  These implants have substantial thickness and sophisticated metallurgy and are able to produce a much stronger construct than that of conventional pins or screws used to surgically fix boney structures.  This implant technology from SI-BONE has been previously used successfully in approximately 1,000 cases of dysfunctional foot joints.

About SI-BONE, Inc.

SI-BONE, Inc. (Cupertino, California) is a leading spinal medical device company dedicated to the development of tools and products for diagnosing and treating patients with low back issues related to sacroiliac (SI) joint pathology.  The company has developed, and is manufacturing and marketing, less invasive approaches using implants for the treatment of SI Joint pathology.  SI-BONE has an experienced management team with extensive experience in orthopedic and spine medical devices.

SOURCE SI-BONE, Inc.


'/>"/>
SOURCE SI-BONE, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Combined Pharma Event Visitor Numbers 5% Ahead of 2008 Frankfurt Record
2. Impact Medical Solutions Announces Initiation of Pilot Clinical Trial and Listing on Frankfurt Stock Exchange
3. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
4. Franklin & Seidelmann Publishes Complex Podiatry MRI Study
5. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
6. NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer
7. Help is Here Express Arrives in Anderson, Seneca
8. HS-7 Document Regarding Research @ M. D. Anderson Orlando
9. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
10. Rosetta Genomics and M. D. Anderson to Develop a MicroRNA-based Diagnostic Test to Identify Risk of Recurrence of Lung Cancer
11. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 22, 2013   Upsher-Smith Laboratories, Inc. ... its global Phase III clinical trial for ... for the management of epilepsy in adults, ... is specifically engineered to provide convenient once-daily ... levels observed with currently available treatment options.  ...
(Date:5/22/2013)...   Life Line Screening  (LLS), a leading ... creation of a unique partnership with MCM Solutions ... is a population health management organization. LLS will provide ... These important expanded services will help MCM and its ... reduces cost of care when individuals are able to ...
(Date:5/22/2013)... -- Ranbaxy Laboratories Limited (hereafter, Ranbaxy), a subsidiary ... announced on May 22 the actions that Ranbaxy ... conduct under prior management ( ... to support Ranbaxy in its efforts to address ... led to the investigations by the U.S. Department ...
Breaking Medicine Technology:Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 2Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 3Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures 4Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2
... Aethlon Medical, Inc., (OTCBB: AEMD) disclosed today that its ... following letter to shareholders. (Photo:   ... Last December, I authored a shareholder letter which referenced ... for innovative new therapeutic strategies to evolve as escalating ...
... Name Medical Center (HNMC) in Teaneck, NJ, announced ... Management (PM) and revenue cycle management (RCM) software ... for distribution to hospital-affiliated physicians under the federal ... testing—including speed, functionality, and interfaces—to reach this benchmark. ...
Cached Medicine Technology:Aethlon Medical Releases Shareholder Letter 2Aethlon Medical Releases Shareholder Letter 3Aethlon Medical Releases Shareholder Letter 4Aprima Earns High Marks at Holy Name Medical Center 2Aprima Earns High Marks at Holy Name Medical Center 3
(Date:5/22/2013)... 22, 2013 People in the United States ... to water shortages. In much of the world, water shortages ... advocate, Sharon Kleyne. She warns against taking water for granted ... is available so easily in the United States. , Sharon ... Water radio show, heard live or by podcast on World ...
(Date:5/22/2013)... Bodybuilding.com is giving back to those who have ... be donating $1 from EVERY purchase made between 12:01am – ... grateful for the men and women who have served our ... founder of Bodybuilding.com. “It’s an honor to give back to ... USA is an amazing organization that supports our nation’s veterans ...
(Date:5/22/2013)... May 22, 2013 Twenty student-led startup ... year participating in an intensive startup accelerator designed to ... or services and create local jobs as part of ... year the Edson initiative offers approximately 20 student teams ... mentorship and training to launch their for-profit, more-than-profit or ...
(Date:5/22/2013)... Researchers in genomic health disparities from the University ... University School of Medicine have teamed up to hold ... Eliminate Health Disparities in Genomic Medicine." The theme ... nonprofits, business and government to reduce these disparities. , ... United States, individuals within underserved groups continue to be ...
(Date:5/22/2013)... report that hospitals may be reaping enormous income ... preventable bloodstream infections contracted in their intensive care ... online in the American Journal of Medical ... patient who develops an avoidable central line-associated bloodstream ... care for than a similar infection-free patient. Moreover, ...
Breaking Medicine News(10 mins):Health News:Water Advocate Sharon Kleyne Announces Water Conservation Appreciation 2Health News:In the Spirit of Memorial Day, Bodybuilding.com is Donating a Portion of Their Sales to Hire Heroes 2Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 2Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 3Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 4Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 5Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 6Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 7Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 8Health News:ASU Announces Edson Student Entrepreneur Initiative’s 2013-2014 Cohort 9Health News:Why We Can't Wait: Conference to Eliminate Health Disparities in Genomic Medicine 2Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4
... among patients on chemotherapy , , SUNDAY, June 1 (HealthDay ... side effects of treatment for head and neck cancer ... of acupuncture. , A new study found significant reductions ... after neck dissection in patients receiving acupuncture. , "Although ...
... evidence for the first time suggests that people suffering ... a progressive worsening of their nasal passage functioning, depending ... a new study published in the June 2008 edition ... study, authored by researchers in Italy, discovered that in ...
... Gemzar, everolimus almost doubled survival time with pancreatic, ... (HealthDay News) -- Patients diagnosed with pancreatic cancer ... nearly doubled their overall survival when the cancer ... shows. , Unfortunately, only about 15 percent of ...
... all subtypes of disease, researchers say , , SATURDAY, May ... trial of the biologic drug Erbitux on patients with ... by about five weeks when combined with chemotherapy. ... but the question has been by how much. , ...
... unanticipated side effects, researchers report , , SATURDAY, May 31 (HealthDay ... risk of breast cancer recurrence in premenopausal women with early ... women who took Zometa (zoledronic acid) had a 30 percent ... other benefits as well. , "We found not only an ...
... NEW YORK (May 29, 2008) -- Leading oncologists ... Center are presenting new basic and clinical research ... Oncology (ASCO) annual meeting in Chicago, May 30 ... presentations and posters to be made by NewYork-Presbyterian/Weill ...
Cached Medicine News:Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Erbitux Plus Chemo Improves Lung Cancer Outcomes 2Health News:Bone Drug Lowers Risk of Breast Cancer Recurrence 2Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 2Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 3Health News:NYP/Weill Cornell physician-scientists present latest cancer findings at ASCO meeting 4
... evenly and safely, the Hoefer GD 2000 uses ... applied beneath the gel through a heavy aluminum ... up to 33 x 44 cm in as ... provides even heat distribution and even vacuum distribution ...
This double-up gel dryer system, 200-240 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... a hot air drying device for polyacrylamide and ... cellophane support for easy viewing. The assembly table ... surface for the drying frame. The dryer holds ... 115 V, 60 Hz system includes a gel ...
The GelAir™ dryer is a component of the GelAir drying system. Supplied as a 115 V, 60 Hz gel drying oven....
Medicine Products: